RBC Capital analyst Daniel Perlin raised the firm’s price target on Global Payments (GPN) to $139 from $130 and keeps an Outperform rating on ...
In a report released on February 11, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback